|
US2021121446A1
|
|
Pharmaceutical compositions of albumin and rapamycin
|
|
WO2020191053A1
|
|
Subcutaneous administration of nanoparticles comprising an mtor inhibitor and albumin for treatment of diseases
|
|
KR20210024471A
|
|
Methods and compositions for treating pulmonary hypertension
|
|
AU2019239953A1
|
|
Methods of treating central nervous system disorders via administration of nanoparticles of an mtor inhibitor and an albumin
|
|
US10705070B1
|
|
Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
|
|
CA3084994A1
|
|
Methods of treating colon cancer using nanoparticle mtor inhibitor combination therapy
|
|
US2018374583A1
|
|
Nomogram and survival predictions for pancreatic cancer
|
|
AU2017343553A1
|
|
Nanoparticle formulations and methods of making and using thereof
|
|
MX2019003694A
|
|
Methods of treating biliary tract cancer.
|
|
EP3518923A1
|
|
Methods of treating mitochondrial and metabolic disorders
|
|
WO2017201189A1
|
|
Methods for assessing neoadjuvant therapies
|
|
KR20180019230A
|
|
The biomarker for the nanoparticle composition
|
|
CN107921006A
|
|
Use the method for nano particle MTOR inhibitor conjoint therapy treatment solid tumor
|
|
MX2017016322A
|
|
Methods of treating epithelioid cell tumors.
|
|
BR112017028132A2
|
|
hematologic malignancy treatment methods using nanoparticle mtor inhibitor combination therapy
|
|
US10527604B1
|
|
Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
|
|
US2018064679A1
|
|
Method for treating cancer based on level of glucocorticoid receptor
|
|
AU2015271950A1
|
|
Nanoparticle comprising rapamycin and albumin as anticancer agent
|
|
US2017202782A1
|
|
Combination therapy comprising nanoparticles of a taxane and albumin with abt-263 in methods for treating cancer
|
|
CN110934852A
|
|
Method of treating bladder cancer
|
